Targeting developmental pathways in children with cancer: what price success? - Wikidata - awgldk - TriplyDB

Targeting developmental pathways in children with cancer: what price success?

Targeting developmental pathways in children with cancer: what price success?

http://www.wikidata.org/entity/Q36905620

about

Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.Targeted approaches to childhood cancer: progress in drug discovery and development.Editorial: Biology-Driven Targeted Therapy of Pediatric Soft-Tissue and Bone Tumors: Current Opportunities and Future Challenges Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.NKG2D ligand expression in pediatric brain tumors.HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma.Bioactivities of ethanol extract from the Antarctic freshwater microalga, Chloromonas sp.Restoring Ovarian Endocrine Function with Encapsulated Ovarian Allograft in Immune Competent Mice.Cell death-based treatment of childhood cancer.Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

P2860

Q35224485-6A7FC3AC-44BE-4187-82B6-3C61A9BC911E Q38105879-3DF1C93B-4F61-45C0-A67A-249697B4DF0F Q38404462-4061AF24-8108-4EAF-A732-3A5448E7AEA7 Q38539783-7CF0757A-1F4F-46D5-8316-E461A984B927 Q38790957-7B244BC0-4202-454B-BD13-DC43ADAA905B Q38961012-B3E79A5D-ECA7-4B05-B572-2CB7BED326CB Q39196323-2E27DD0E-9CAB-442D-83B7-BA4C47DD61D8 Q39361446-EC883ED0-DE74-496F-B25E-5CBB6EF1AA9F Q41078068-57571FEB-B195-4A0E-913D-11BE30E337D2 Q47139421-BA1B7AE8-679E-4523-84A7-CA5FD549806E Q49679684-A37021B9-3900-4868-990C-2EA933BEE20D Q52677126-82874A64-8CD1-4D17-BC11-5FC8A47E8B52

P2860

Targeting developmental pathways in children with cancer: what price success?

http://www.wikidata.org/entity/Q36905620

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Targeting developmental pathways in children with cancer: what price success?

@en

type

label

Targeting developmental pathways in children with cancer: what price success?

@en

prefLabel

Targeting developmental pathways in children with cancer: what price success?

@en

P1433

Q36905620-3ED8DBC5-A772-4FCB-B4F5-96E9BB61601E

P1476

Q36905620-05D09754-9953-4DC2-8BA1-A6A8665B0A1D

P2093

Q36905620-63019469-8F56-4EE3-91EF-567E7EFED832

P2860

Q36905620-0A9B6A1C-86AE-4AB9-A139-2B4A1ABB3424

Q36905620-0E2D6012-184A-4E59-9E97-30FB9ACFA679

Q36905620-11B38243-CC24-4F80-908F-C2F278912760

Q36905620-1CBB30B8-C95B-43E7-887C-10FF8CDA9DEB

Q36905620-246E7928-49BC-4372-966D-18C9F3547982

Q36905620-2B647C19-B908-4034-B22D-B7068EF2B313

Q36905620-2B9CFCE7-5945-48E0-8F46-0BFA7BADF440

Q36905620-2C67BD8A-091B-42D7-B5D0-4C4EB038B102

Q36905620-3ED6F1D8-6569-40D7-AEE5-9FE06B8B68AB

Q36905620-42BD32FF-5DA6-46EB-A621-DE49056ED355

P304

Q36905620-E3B8D70E-6B44-474E-9939-3FB0C5104E51

P31

Q36905620-F2452BC4-BA61-4E68-8480-93B7112B4751

P356

Q36905620-6311558D-E4CA-4CE1-9BC5-8C575FCB00DD

P433

Q36905620-83C2C936-0481-4854-8FA4-7428E91BA4B0

P478

Q36905620-53AA198A-F16D-4A4D-91D2-D4735D21C16F

P50

Q36905620-8DF7213E-109E-4810-993B-F31CDF11B5E3

Q36905620-A2DF19EC-4138-4F5B-9561-B4A39FDBB6DA

P577

Q36905620-90B3D733-D37E-409C-85D0-18E76C7CFF5F

P698

Q36905620-266F853F-1C1C-4750-9174-7A044229EE1C

P932

Q36905620-64AB1C5C-CCAC-414A-A1E3-EC50F8F38215

P356

S1470-2045(12)70530-2

P1433

The Lancet Oncology

P1476

Targeting developmental pathways in children with cancer: what price success?

@en

P2093

Lia Gore

http://www.w3.org/2001/XMLSchema#string

P2860

Profound block in thymocyte development in mice lacking p56lck

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Skin toxicities associated with epidermal growth factor receptor inhibitors

The emerging normal and disease-related roles of anaplastic lymphoma kinase

Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?

Evolved tumor suppression: why are we so good at not getting cancer?

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension

Cancer. Addiction to oncogenes--the Achilles heal of cancer

Principles of cancer therapy: oncogene and non-oncogene addiction

Synthetic lethal screen identification of chemosensitizer loci in cancer cells.

P304

e70-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(12)70530-2

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Christopher C. Porter

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23369685

http://www.w3.org/2001/XMLSchema#string

P932

3673778

http://www.w3.org/2001/XMLSchema#string